Steve Pakola

Chief Medical Officer @REGENXBIO

Irvington, NY, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Apr 2019 — Present

Chief Medical Officer @REGENXBIO

View department →

Lead Medical Organization (Clinical Development/Operations, Drug Safety, Regulatory, Biometrics, Medical Affairs), built from 40 to 80 leaders strong, across ophthalmology and rare disease programs *Led clinical transformation from early-stage to late-stage company, with multiple programs advanced into pivotal clinical development • Design and execution of largest pivotal gene therapy clinical program ever. • Design and execution of first ever trials evaluating Gene Therapy delivery to novel space (suprachoroidal delivery for wet AMD and DR) • Advancement of Gene Therapy trials for treatment of serious, rare, monogenic diseases via CNS delivery (MPS-II and -1). • Translation of preclinical programs into clinical development (Successful IND filing for RGX-202 for Duchenne, and CTA for RGX-381 for CLN2 ocular)*Led Medical Organization component of Abbvie global strategic partnership for RGX-314 program ($370 million upfront with up to $1.38 billion in additional milestones)

EDUCATION

1986 — 1994

University of Pennsylvania

BA, MD

ABOUT STEVE PAKOLA

Industry Leader with over 25 years of biopharmaceutical experience, including over 20…

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Steve Pakola — Chief Medical Officer at REGENXBIO in Irvington, NY, US | Unifers